Erytech Pharma S.A. (ERYP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ERYP Stock Summary
- Of note is the ratio of Erytech Pharma SA's sales and general administrative expense to its total operating expenses; just 9.52% of US stocks have a lower such ratio.
- With a price/sales ratio of 24.22, Erytech Pharma SA has a higher such ratio than 91.52% of stocks in our set.
- With a year-over-year growth in debt of 183.88%, Erytech Pharma SA's debt growth rate surpasses 94.36% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Erytech Pharma SA, a group of peers worth examining would be VNE, MESO, TTNP, TDW, and AUMN.
- Visit ERYP's SEC page to see the company's official filings. To visit the company's web site, go to www.erytech.com.
ERYP Stock Price Chart Interactive Chart >
ERYP Price/Volume Stats
|Current price||$5.46||52-week high||$13.95|
|Prev. close||$5.26||52-week low||$5.00|
|Day high||$5.46||Avg. volume||18,585|
|50-day MA||$6.55||Dividend yield||N/A|
|200-day MA||$7.78||Market Cap||140.78M|
Erytech Pharma S.A. (ERYP) Company Bio
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France.
ERYP Latest News Stream
|Loading, please wait...|
ERYP Latest Social Stream
View Full ERYP Social Stream
Latest ERYP News From Around the Web
Below are the latest news stories about Erytech Pharma SA that investors may wish to consider to help them evaluate ERYP as an investment opportunity.
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2)
ERYTECH to Participate in Upcoming Virtual Investor Conferences in June Lyon (France) and Cambridge, MA (U.S.), May 26, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its partipation in the following investor conferences in the month of June. Jefferies Virtual Healthcare Conference – June 1- 4, 2021 Gil Beyen, Chief Executive Officer, will be participating in a fireside chat followed by a virtual Q&A session on Friday June 4th at 10am (ET). WEBCAST LINK A replay of the session will be on the Jefferies conference website, as well as on ERYTECH’s website, under the “Investors” section at investors.erytech.com, for 30-days followi...
ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting SS RELEASE Lyon (France), May 25, 2020 – Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that its Combined Shareholders’ Meeting will be held in French in closed session at 2pm CEST on Friday, June 25, 2021, and also the associated details. In compliance with recent French legislation1 and per the recommendations of the French financial markets authority (Autorité des Marchés Financiers or AMF), Erytech confirms that its Annual Ordinary and Extraordinary Shareho...
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021 Conference call and webcast on Wednesday, May 5, 2021at 8:30am EST/ 2:30pm CET TRYbeCA-1, Phase 3 clinical trial in 2nd line pancreatic cancer, fully enrolled, and on track for final results in Q4 2021Pre-BLA meeting with FDA requested to discuss the potential submission of a Biologics License Application (BLA) for eryaspase in hypersensitive ALL in the second half of this yearFirst dose cohort in Phase 1 Investigator Sponsored Trial (IST) in 1st line pancreatic cancer completed with no dose limiting toxicity; encouraging signs of clinical activity observedCash and cash equivalents of €37.4 million ($43.9 million) at the end of March 2021Successful registered direct round of $ 30 million with sp...
ERYTECH to Participate in Upcoming Virtual Investor Conferences in April Lyon (France) and Cambridge, MA (U.S.), April 7, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in the following conferences in the month of April and engage in select one-on-one investor meetings alongside members of the senior management. SMALLCAP EVENT®- CF&B Communication – April 14-15, 2021 Gil Beyen, Chief Executive Officer, will participate in one-on-one meetings from 8am to 1pm ET (02:00pm to 07:00pm CEST). For more information about the CF&B Communication’s SMALLCAP EVENT, please refer to t...
ERYP Price Returns